Brimonidine ophthalmic Alternatives Compared
| Brimonidine ophthalmic | Lumify (brimonidine) | Fluorometholone ophthalmic |
|
|---|
| Brimonidine ophthalmic | Lumify (brimonidine) | Fluorometholone ophthalmic |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription and OTC
Prescribed for Eye Redness, Glaucoma - Open Angle, Intraocular Hypertension. Brimonidine ophthalmic may also be used for purposes not listed in this medication guide. |
Over-the-counter
Prescribed for Eye Redness. Lumify may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Eyelash Hypotrichosis, Eye Redness/Itching, Steroid Responsive Inflammatory Conditions, Eye Redness, Allergies. Fluorometholone ophthalmic may also be used for purposes not listed in... View more |
Related suggestions |
|||||||||||||||||||||||
| More about Brimonidine ophthalmic | More about Lumify (brimonidine) | More about Fluorometholone ophthalmic | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Brimonidine ophthalmic has an average rating of 3.4 out of 10 from a total of 193 ratings on Drugs.com. 21% of reviewers reported a positive effect, while 70% reported a negative effect. |
Lumify has an average rating of 3.2 out of 10 from a total of 175 ratings on Drugs.com. 19% of reviewers reported a positive effect, while 73% reported a negative effect. |
Fluorometholone ophthalmic has an average rating of 6.3 out of 10 from a total of 11 ratings on Drugs.com. 45% of reviewers reported a positive effect, while 27% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
View all Brimonidine ophthalmic side effects |
View all Lumify side effects |
|||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
Lower cost generic |
Lower cost generic approved |
Lower cost generic |
||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Brimonidine ophthalmic prices |
View all Lumify prices |
View all Fluorometholone ophthalmic prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Alphagan P, Lumify, Lumify Preservative Free, Qoliana | Other brimonidine brands include: Alphagan P, Lumify Preservative Free, Qoliana | Eflone, Flarex, FML, FML Forte Liquifilm, FML Liquifilm, FML S.O.P. | ||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 369 drugs are known to interact with Brimonidine ophthalmic:
|
A total of 369 drugs are known to interact with Lumify:
|
A total of 42 drugs are known to interact with Fluorometholone ophthalmic:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
N/A |
December 22, 2017 |
N/A |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
|
N/A |
||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.